nach oben

PharmacoEconomics

Erschienen in:

01.12.2012 | Systematic Review

Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis

A Critical and Systematic Review

verfasst von: Cécile Gaujoux-Viala, Bruno Fautrel, MD, PhD

Erschienen in: PharmacoEconomics | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This report reviews the cost effectiveness of different therapeutic interventions used in the treatment of ankylosing spondylitis (AS).

Methods

We performed a systematic search of the databases MEDLINE via PubMed, EMBASE and the Cochrane Library and used hand-searching to identify articles on cost effectiveness of therapies for adult patients with AS published up to November 2010.

Results

Of 135 articles, 13 studies were analysed. Two articles were on physical therapies, one article was on NSAIDs and ten articles were on tumour necrosis factor (TNF) inhibitors (infliximab = 6, etanercept = 2, infliximab and etanercept = 1 and adalimumab = 1). Of the latter, no article directly compared TNF inhibitors. Articles showed substantial heterogeneity in methodological approaches and thus results, which prevented us from any extensive comparison, data pooling or meta-analysis. The incremental cost-effectiveness ratio (ICER) for spa-exercise treatment was €7465 (95% CI 3294, 14 686) per QALY. The ICERs for infliximab, etanercept and adalimumab were €5307–237 010, €29 815–123 761 and €7344-33 303 per QALY, respectively.

Conclusions

Modelling treatment strategies in chronic relapsing diseases such as AS presents specific challenges, as reflected in the variation in the cost-effectiveness results reported. Although quite variable, the cost-effectiveness ratios for AS therapies remain within an acceptable range.

Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998 Jan; 41(1): 58–67CrossRef

Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. [letter]. Arthritis Rheum 2005 Dec; 52(12): 4048–9; author reply 4049–50CrossRef

Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005 Oct; 64(10): 1431–5CrossRef

Han C, Robinson Jr DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006 Nov; 33(11): 2167–72PubMed

Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006 Apr; 65(4): 442–52CrossRef

Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 Apr 6; 359(9313): 1187–93CrossRef

Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003 Jun; 48(6): 1667–75CrossRef

van der Heijde D, Landewé R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005 Jul; 52(7): 1979–85CrossRef

Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 Aug; 44(8): 1876–86CrossRef

10.

Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 Dec; 21(12): 2286–91PubMed

11.

Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 Dec; 21(12): 2281–5PubMed

12.

Van Tubergen A, Boonen A, Landewé R, et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002 Oct 15; 47(5): 459–67CrossRef

13.

Bakker C, Hidding A, van der Linden S, et al. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis: a randomized controlled trial. J Rheumatol 1994 Feb; 21(2): 264–8PubMed

14.

Jansen JP, Gaugris S, Choy EH, et al. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010 Apr 1; 28(4): 323–44CrossRef

15.

Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004 Sep; 43(9): 1158–66CrossRef

16.

Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006 Apr; 33(4): 732–40PubMed

17.

Kobelt G, Sobocki P, Sieper J, et al. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int J Technol Assess Health Care 2007; 23(3): 368–75CrossRef

18.

Kobelt G, Sobocki P, Mulero J, et al. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data. Scand J Rheumatol 2008 Jan–Feb; 37(1): 62–71CrossRef

19.

Boonen A, van der Heijde D, Severens JL, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006 Feb; 65(2): 201–8CrossRef

20.

Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009 Jul; 36(7): 1421–8CrossRef

21.

Fautrel B, Benhamou M, Breban M, et al. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. Ann Rheum Dis 2010 Feb; 69(2): 424–7CrossRef

22.

Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) 2007 Aug; 46(8): 1338–44CrossRef

23.

Neilson AR, Sieper J, Deeg M. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford) 2010 Nov; 49(11): 2122–34CrossRef

24.

Botteman MF, Hay JW, Luo MP, et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 2007 Aug; 46(8): 1320–8CrossRef

25.

Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095–108CrossRef

26.

Oldroyd J, Schachna L, Buchbinder R, et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database. Int J Rheumatol 2009; 268569

27.

Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004 Nov; 42(11): 1125–31CrossRef

28.

National Institute for Health and Clinical Excellence. Incorporating health economics in guidelines and assessing resource impact. In: NICE. The guidelines manual. London: NICE, 2007: 49–55 [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter8.pdf [Accessed 2012 Sep 11]

29.

Boonen A, Maetzel A, Drummond M, et al. The OMER-ACT initiative: towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol 2009 Sep; 36(9): 2045–9CrossRef

30.

Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 Sep–Oct; 7(5): 518–28CrossRef

31.

Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health 2009 Mar; 12 Suppl. 1: S10–5CrossRef

32.

Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22(13): 857–76CrossRef

Titel: Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis
A Critical and Systematic Review
verfasst von: Cécile Gaujoux-Viala
Bruno Fautrel, MD, PhD
Publikationsdatum: 01.12.2012
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 12/2012
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/11596490-000000000-00000

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

A Systematic Review and Critical Assessment of Health State Utilities

Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets

Acknowledgement

What’s Good and Bad About Contraceptive Products?

Chemotherapy Administration

Bevacizumab for Metastatic Colorectal Cancer